June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Biomarkers from clinic deployable, multiplex, diagnostic test stratifies ocular surface disease and sub-clinical inflammation in patients.
Author Affiliations & Notes
  • Sailie Shirodkar
    Narayana Nethralaya, Bangalore, Karnataka, India
  • Rohit Shetty
    Narayana Nethralaya, Bangalore, Karnataka, India
  • Archana Padmanabhan Nair
    Narayana Nethralaya, Bangalore, Karnataka, India
  • Pooja Khamar
    Narayana Nethralaya, Bangalore, Karnataka, India
  • Swaminathan Sethu
    Narayana Nethralaya, Bangalore, Karnataka, India
  • Arkasubhra Ghosh
    Narayana Nethralaya, Bangalore, Karnataka, India
  • Footnotes
    Commercial Relationships   Sailie Shirodkar None; Rohit Shetty None; Archana Padmanabhan Nair None; Pooja Khamar None; Swaminathan Sethu None; Arkasubhra Ghosh None
  • Footnotes
    Support  This work was supported by Narayana Nethralaya Foundation and NovoMol-Dx, Bangalore, India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of this abstract.
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 423. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sailie Shirodkar, Rohit Shetty, Archana Padmanabhan Nair, Pooja Khamar, Swaminathan Sethu, Arkasubhra Ghosh; Biomarkers from clinic deployable, multiplex, diagnostic test stratifies ocular surface disease and sub-clinical inflammation in patients.. Invest. Ophthalmol. Vis. Sci. 2022;63(7):423.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The pathology of most ocular conditions is driven by a number of known molecular pathways. However, targeted management requires tear-based, rapid, multiplexed diagnostic systems in the clinical setting. We deployed such a system that measures 8 soluble factors in the cornea clinic to stratify patients based on correlations between clinical indices and biomarker levels

Methods : We tested tear samples collected from 621 eyes categorised clinically into controls(n=214), dry eye disease(DED; n=107), Keratoconus(KC; n=125) based on slit lamp examination, ocular surface disease index(OSDI) scoring, dry eye evaluation and ocular surface staining. Tear fluid collected using Schirmer’s strips were evaluated for soluble factors on a customised multiplex ELISA platform (Bio-M Pathfinder). Another group of clinically healthy subjects were further stratified into – sub-clinical inflammation (SCI) groups 1(n=95) and 2(n=80) based on the level of biomarkers and correlation to clinical indices.

Results : Patients with DED showed significantly higher OSDI scores, MMP9, IL6, TNFα, IL1β, IL17A and sICAM1 levels with reduced Schirmer’s test and TBUT values. KC eyes showed significantly higher MMP9 levels. IL10 and VEGF levels remained unchanged across the conditions. SCI-1 and SCI-2 groups had significantly higher inflammatory markers, significantly reduced Schirmer’s and TBUT levels which were not low enough to be clinically classified as DED. Inflammatory biomarker detection was successful in all cases with good reproducibility, high sensitivity and specificity.

Conclusions : Clinical usage of a rapid, biomarker platform is feasible and useful to identify subjects with sub-clinical inflammation, helping stratify subjects for customised treatments and surgery.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×